![Professor Claude Wischik Professor Claude Wischik](https://www.abdn.ac.uk/img/200x200/staffpages/assets/images/default-profile-picture.jpg)
Professor Claude Wischik
Chair in Mental Health (Clin)
- About
-
- Email Address
- c.m.wischik@abdn.ac.uk
- Office Address
TauRx Therapeutics Ltd
1st Floor, Sir Moir Lockhead Building
395 King Street
Aberdeen
AB24 5RP
United Kingdom
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Research
-
Research Overview
Molecular Neuropathology of Alzheimer's Disease, and in particular the therapeutic intervention of tau pathology
- Publications
-
Page 6 of 11 Results 51 to 60 of 103
The effect of latent confounding processes on the estimation of the strength of causal influences in chain-type networks
Medical Research Archives , vol. 5, no. 9, 1298Contributions to Journals: ArticlesOrganisation of cortical thickness networks in Alzheimer’s disease and behavioural variant frontotemporal dementia across brain lobes
6th Cambridge Neuroscience SymposiumContributions to Conferences: AbstractsMethod and system for determining network connections
Patents: PatentsLMTM DECREASES α-SYNUCLEIN PATHOLOGY AND REDUCES BEHAVIOURAL DEFECTS IN α-SYNUCLEIN TRANSGENIC MICE
Alzheimer's and Dementia, vol. 13, no. 7 Suppl., pp. P945-P945Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1016/j.jalz.2017.06.1854
Monoaminergic Neuropathology in Alzheimer's disease
Progress in Neurobiology, vol. 151, pp. 101-138Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.pneurobio.2016.04.001
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/8480/1/ProgN_Simic.pdf
Distinct anatomical subtypes of behavioural variant frontotemporal dementia and involvement of intrinsic brain networks: a clustering study
Alzheimer Research UK (2017)Contributions to Conferences: AbstractsAssays for the Screening and Characterization of Tau Aggregation Inhibitors
Tau Protein: Methods and Protocols. Smet-Nocca, C. (ed.). Springer, pp. 129-140, 12 pagesChapters in Books, Reports and Conference Proceedings: Chapters (Peer-Reviewed)- [ONLINE] DOI: https://doi.org/10.1007/978-1-4939-6598-4_8
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
The Lancet, vol. 388, no. 10062, pp. 2873-2884Contributions to Journals: ArticlesInhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges. Wolfe, M. S. (ed.). Elsevier Inc., pp. 385-436, 52 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1016/B978-0-12-802173-6.00015-0
- [ONLINE] View publication in Scopus
Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease
Biomolecules, vol. 6, no. 2, pp. 1-19Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3390/biom6020019
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/5864/1/biomolecules_06_00019_v2.pdf